No Data
Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion
Leerink Partners Maintains Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $89
Express News | Janux Therapeutics Inc : Leerink Partners Cuts Target Price to $89 From $91
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $36 to $100
Janux Therapeutics Price Target Lowered to $36 From $41 at Scotiabank
Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH), Immunocore Holdings (IMCR) and Janux Therapeutics Inc (JANX)